Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMM 02: Ruxolitinib versus allogeneic stem cell transplantation in myelofibrosis by donor availability
2014-005210-28Phase 2Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Dec 2015
- Modality
- Small Molecules, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ruxolitinib and allogeneic hematopoietic stem cell transplantation in myelofibrosis (MF) and primary myelofibrosis (PMF) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Event-free survival. Started Dec 2015; status: completed.
02
Drugs
ruxolitiniballogeneic hematopoietic stem cell transplantation
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)
Beyond the preview
Go deeper on 2014-005210-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005210-28.